The new world of biosimilars in oncology: Translation of data to the clinic

Affiliations

¹ University of California San Francisco Comprehensive Cancer Center, USA. Electronic address: hope.rugo@ucsf.edu.
² Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology, Barcelona, Spain; IOB Institute of Oncology, Quiron Group, Madrid & Barcelona, Spain.

Editorial

Hope S Rugo et al. Eur J Cancer. 2018 Jun.

. 2018 Jun:96:125-127.

doi: 10.1016/j.ejca.2018.03.005. Epub 2018 Apr 18.

¹ University of California San Francisco Comprehensive Cancer Center, USA. Electronic address: hope.rugo@ucsf.edu.
² Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology, Barcelona, Spain; IOB Institute of Oncology, Quiron Group, Madrid & Barcelona, Spain.

No abstract available

Comment on

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results.
Pivot X, Bondarenko I, Nowecki Z, Dvorkin M, Trishkina E, Ahn JH, Im SA, Sarosiek T, Chatterjee S, Wojtukiewicz MZ, Shparyk Y, Moiseyenko V, Bello M 3rd, Semiglazov V, Lee Y, Lim J. Pivot X, et al. Eur J Cancer. 2018 Apr;93:19-27. doi: 10.1016/j.ejca.2018.01.072. Epub 2018 Feb 12. Eur J Cancer. 2018. PMID: 29448072 Clinical Trial.